Efficacy Of Continuous S(+)-ketamine Infusion For Postoperative Pain Control: A Randomized Placebo-controlled Trial by de Paula Gomes Miziara et al.
Clinical Study
Efficacy of Continuous S(+)-Ketamine
Infusion for Postoperative Pain Control:
A Randomized Placebo-Controlled Trial
Luiz Eduardo de Paula Gomes Miziara,1 Ricardo Francisco Simoni,1,2
Luís Otávio Esteves,1 Luis Henrique Cangiani,1
Gil Fernando Ribeiro Grillo-Filho,1 and Anderson Garcia Lima e Paula1
1Department of Anesthesiology, Centro Me´dico Campinas, Rua Edilberto Luis Pereira da Silva 150, Campinas, SP, Brazil
2Department of Pharmacology, Universidade de Campinas (UNICAMP), Centro Me´dico Campinas,
Rua Edilberto Luis Pereira da Silva 150, 13083-190 Campinas, SP, Brazil
Correspondence should be addressed to Luiz Eduardo de Paula Gomes Miziara; miziara.luiz@cmcnet.com.br
Received 21 September 2015; Accepted 10 January 2016
Academic Editor: Jean Jacques Lehot
Copyright © 2016 Luiz Eduardo de Paula Gomes Miziara et al. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Aim. A double-blind, randomized, placebo-controlled trial was designed to evaluate the efficacy of continuous intraoperative
infusion of S(+)-ketamine under intravenous anesthesia with target-controlled infusion of remifentanil and propofol for
postoperative pain control. Methods. Forty-eight patients undergoing laparoscopic cholecystectomy were assigned to receive
continuous S(+)-ketamine infusion at a rate of 0.3mg⋅kg−1⋅h−1 (𝑛 = 24, intervention group) or an equivalent volume of saline
at the same rate (𝑛 = 24, placebo group). The same target-controlled intravenous anesthesia was induced in both groups. Pain was
assessed using a 0 to 10 verbal numeric rating scale during the first 12 postoperative hours. Pain scores and morphine consumption
were recorded in the postanesthesia care unit (PACU) and at 4 and 12 hours after surgery. Results. Pain scores were lower in
the intervention group at all time points. Morphine consumption did not differ significantly between groups during PACU stay,
but it was significantly lower in the intervention group at each time point after PACU discharge (𝑃 = 0.0061). At 12 hours after
surgery, cumulative morphine consumption was also lower in the intervention group (5.200 ± 2.707) than in the placebo group
(7.525 ± 1.872). Conclusions. Continuous S(+)-ketamine infusion during laparoscopic cholecystectomy under target-controlled
intravenous anesthesia provided better postoperative pain control than placebo, reducingmorphine requirement.Trial Registration.
This trial is registered with ClinicalTrials.gov NCT02421913.
1. Introduction
Postoperative pain control with multimodal analgesia is
important not only to relieve pain but also to reduce post-
operative side effects, such as nausea, vomiting, need for
sedation, and length of hospital stay. Therefore, adjuvant
drugs with proven efficacy in this type of analgesia are very
useful for anesthesiologists.
Several experimental and clinical studies suggest that
the administration of potent short-acting opioids, such as
remifentanil, is associated with central sensitization to pain,
a phenomenon known as opioid-induced hyperalgesia [1–4].
The activation of N-methyl-D-aspartate (NMDA) receptors
has been suggested to be the mainmechanism facilitating the
response to sensory stimuli and leading to opioid-induced
hyperalgesia, along with a state of excitability in the spinal
cord dorsal horn.
One of the two subunits of the NMDA, namely, sub-
unit 2B (NR2B), has an important role in the genesis of
remifentanil-induced hyperalgesia and inflammatory hyper-
algesia caused by the induction of long-term potentiation. A
previous study found that increased tyrosine phosphoryla-
tion in this subunitmay be preventedwith the use of ketamine
[5].
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Although ketamine acts on several receptors, its analgesic
effects result mainly from the fact that it is a NMDA receptor
antagonist that prevents central sensitization [2, 6] and
inhibits this receptor by reducing mean time and frequency
of NMDA receptor channel opening, the latter through an
allosteric mechanism. Therefore, ketamine has been widely
used to investigate the role of the NMDA receptor in several
animal and human models.
S(+)-ketamine is a ketamine isomer that acts by changing
channel opening time through noncompetitive blockade [7].
Furthermore, compared with the racemic mixture, it has
a twofold higher analgesic potency [7, 8] and a three- to
fourfold greater affinity for the intrachannel phencyclidine
receptor site, which is the site of action of S(+)-ketamine.
The present study was designed to evaluate the efficacy
of continuous intraoperative infusion of S(+)-ketamine for
pain control after laparoscopic cholecystectomy under target-
controlled total intravenous anesthesia, testing the hypothesis
that S(+)-ketamine is more effective than placebo in the
control of postoperative pain.
2. Methods
This double-blind, randomized, placebo-controlled trial was
conducted at Centro Me´dico Campinas, Brazil, from June
2012 to February 2014, and participants were recruited among
patients scheduled for laparoscopic cholecystectomy during
this period. After approval of the study by the Research Ethics
Committee, all participants signed the informed consent
form. The trial is registered at ClinicalTrials.gov, number
NCT02421913. Eligible participants were all patients aged 18–
65 years with American Society of Anesthesiologists Physical
Status (ASA PS) classes 1-2. Exclusion criteria were use of
alcohol or illicit drugs, H2 inhibitors, opioids, or calcium
channel blockers in the last 10 days, chronic pain, myocardial
ischemia, or psychiatric disorders.
Sample size was calculated based on the results of a
previous pilot study. To detect a difference of at least 38% in
pain scores in the postanesthesia care unit (PACU) between
the intervention and placebo groups, with an alpha error of
5% and a beta error of 20%, a sample size of at least 21 patients
per group was required to achieve 80% power and a 95%
confidence interval. Three more patients were added to each
group to account for possible losses to follow-up during the
trial.
Participants were randomly assigned in a 1 : 1 ratio
to receive either S(+)-ketamine or placebo during laparo-
scopic cholecystectomy. The randomization sequence was
created by an anesthesiologist with no involvement in
the care of participants using the Randomizer software
(https://www.randomizer.org/). All participants and the
anesthesiologist performing the laparoscopic cholecystec-
tomy were kept blind to group assigment. The allocation
sequence was concealed in sequentially numbered, sealed
envelopes. In order to preserve the double-blind nature of
the study, the envelopes were opened by a third person with
no involvement in the anesthetic procedure, who prepared a
50mL syringe containing either S(+)-ketamine (intervention
group) or saline (placebo group). In case of emergency, the
anesthesiologist responsible for the care of the patient was
allowed to violate the protocol and be informed about the
group to which the patient was assigned.
No preanesthetic medication was administered to pa-
tients. Mean noninvasive blood pressure (MBP), ECG, pulse
oximetry (SpO
2
), bispectral index (BIS), and capnography
were monitored in all patients after tracheal intubation.
After venipuncture, patients received intravenous pare-
coxib sodium (40mg). Anesthesia was induced withmidazo-
lam at a dose of 0.05mg⋅kg−1 and target-controlled infusions
of propofol (target dose of 3.0𝜇⋅mL−1) and remifentanil (tar-
get dose of 6.0 ng⋅mL−1) using the Marsh pharmacokinetic
model with ke0 of 1.21min−1 and theMinto pharmacokinetic
model, respectively. Unconsciousness was determined by loss
of corneal and palpebral reflexes and confirmed by a BIS
< 50. Rocuronium (0.6mg⋅kg−1) was then administered.
Immediately after tracheal intubation, the target dose of
propofol was adjusted tomaintain BIS between 35 and 50 and
the target dose of remifentanil was reduced to 3 ng⋅mL−1. Five
minutes before surgery, patients assigned to the intervention
group received continuous S(+)-ketamine infusion at a rate of
0.3mg⋅kg−1⋅h−1, and patients assigned to the placebo group
received an equivalent volume of saline at the same rate.
At the beginning of surgery, the target dose of remifen-
tanil was increased to 5 ng⋅mL and adjusted intraoperatively
to maintain MBP ± 15% of baseline levels, while the target
dose of propofol was adjusted intraoperatively to maintain
BIS between 35 and 50. At the end of the procedure,
neuromuscular blockade was reversed with sugammadex.
Additionally, propofol and remifentanil infusions were dis-
continued, as well as S(+)-ketamine and saline infusions in
the intervention and placebo groups.
The duration of anesthesia, duration of surgery, time
until awakening (spontaneous opening of the eyes and/or
BIS > 70), and overall dose of S(+)-ketamine, remifentanil,
and propofol infused per total body weight were recorded.
Patients were extubated in the operating room and trans-
ferred to the PACU, where postoperative pain was assessed
using a 0 to 10 verbal numeric scale (VNS). Patients were
considered pain-free if they scored ≤2 and in pain if they
scored ≥3 on the VNS. Morphine was administered at a
dose of 0.05mg⋅kg−1 when the patient reported pain for
the first time and at a dose of 0.025mg⋅kg−1 on subsequent
occasions. Pain scores were recorded in the PACU and at
4 and 12 hours after the end of surgery, and patients were
continuously monitored during their PACU stay by one of
the anesthesiologists responsible for this clinical trial. Patients
were assessed by the same anesthesiologist every 20 minutes
after being discharged from PACU and within the first 4
hours after surgery and every 40 minutes from the fourth to
the twelfth hour after surgery. All patients were instructed to
call for the presence of the anesthesiologist responsible for
the surgical procedure, either verbally or using an individual
alarm device, at any time between these assessments in case
of pain or any other unpleasant effect.
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Figure 1: Patient flow chart.
Parametric variables were analyzed using Student’s 𝑡-
test, and nonparametric variables were analyzed using the
Mann-Whitney 𝑈 test. Variables were expressed as mean
and standard deviation (SD). Differences were considered
significant when the 𝑃 value was less than 0.05.
3. Results
A total of 48 patients were enrolled in the trial: 24 were ran-
domized to S(+)-ketamine and 24 to placebo. Three patients
from the placebo group refused to participate in the study. Of
24 patients who received continuous S(+)-ketamine infusion,
three were excluded for protocol violation. Therefore, the
final analysis included 42 patients, 21 in the S(+)-ketamine
group and 21 in the placebo group (Figure 1).
Patients’ demographic data were similar in both groups.
There was no difference between groups regarding duration
of surgery, duration of anesthesia, and time until awakening.
There was no significant statistical difference between the two
groups with regard to length of stay, but all patients stayed at
the unit for 120 minutes for a more accurate evaluation of the
outcomes of interest.
Mean (SD) remifentanil consumption was 0.170
(0.054)mcg⋅kg−1⋅min−1 in the S(+)-ketamine group and
0.228 (0.042)mcg⋅kg−1⋅min−1 (𝑃 = 0.0175) in the placebo
group, and mean (SD) propofol consumption was 72.194
(11.539)mcg⋅kg−1⋅min−1 in the S(+)-ketamine group and
84.895 (13.739)mcg⋅kg−1⋅min−1 in the placebo group, with a
significant difference between groups (𝑃 = 0.0286).
Median pain scores on the VNS during PACU stay were
5.5 in the S(+)-ketamine group and 8.5 in the placebo group
(𝑃 < 0.0001). Pain scores decreased to 0.0 in the S(+)-ket-
amine group and 7.0 in the placebo group (𝑃 = 0.0004) at 4
hours after surgery and to 0.0 and 5.0, respectively, at 12 hours
after surgery (𝑃 = 0.0309) (Figure 2).
There was no difference in morphine consumption dur-
ing PACU stay between patients who received S(+)-ketamine
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Figure 2: Pain scores during PACU stay and at 4 and 12 h after
surgery. PACU: postanesthesia care unit; PG: placebo group; SG:
S(+)-ketamine group.
(4.00 [SD, 2.29]mg) and placebo (4.30 [SD, 0.83]mg) (𝑃 =
0.5770). The mean (SD) dose of morphine used was 0.750
(1.198)mg in the S(+)-ketamine group and 1.825 (0.689)mg in
the placebo group (𝑃 = 0.0108) from PACUdischarge up to 4
hours after surgery and 0.450 (0.93)mg and 1.400 (0.99)mg,
respectively, (𝑃 = 0.0089) between 4 and 12 hours after
surgery, with statistically significant differences at these time
points. Cumulative morphine consumption was significantly
lower in the S(+)-ketamine group than in the placebo group
(5.200 [SD, 2.707]mg versus 7.525 [SD, 1.872]mg;𝑃 = 0.0061)
(Figure 3).
The following postoperative side effects were recorded:
nausea (1 patient in the S(+)-ketamine and 2 patients in the
placebo group), agitation (2 patients in the S(+)-ketamine
group), and hallucination (1 patient in the S(+)-ketamine
group), with no difference between groups.
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Figure 3: Morphine consumption during PACU stay and at 4 and
12 h after surgery. 4 h–12 h: from 4 to 12 h after surgery; PACU:
postanesthesia care unit; PACU-4 h: from PACU discharge up to 4 h
after surgery; PG: placebo group; SG: S(+)-ketamine group.
4. Discussion
In the current study, continuous intraoperative infusion of
S(+)-ketamine (at a rate of 0.3mg⋅kg−1⋅h−1) in patients under
intravenous anesthesia with target-controlled infusion of
remifentanil and propofol provided better postoperative pain
control than placebo over the first 12 hours after laparoscopic
cholecystectomy.
Continuous infusion of remifentanil has been associated
with the development of opioid-induced hyperalgesia [9,
10]. Experimental studies have shown that patients become
rapidly tolerant to infusion of potent short-acting opioids
such as remifentanil. The mechanisms involved in this tol-
erance include activation of NMDA receptors in the spinal
cord dorsal horn [2, 6, 11], inactivation of 𝜇-opioid receptors
[12], spinal dynorphin release [13], and upregulation of cyclic
adenosine monophosphate [14].
The time of recovery from anesthesia with remifentanil is
relatively dose independent. Thus, this drug can be adminis-
tered at high doses during surgery with low risk of delayed
postoperative recovery or respiratory depression. However,
high doses of remifentanil administered intraoperatively are
more closely related to the induction of postoperative sec-
ondary hyperalgesia as compared to long-acting opioids [2, 4,
15], requiring higher doses of morphine in the postoperative
period to provide appropriate analgesia [16]. In a study
with healthy human volunteers, a skin area with preexisting
mechanical hyperalgesia was significantly enlarged 60–90
minutes after remifentanil infusion [17].
NMDA receptors are complexes formed by at least two
types of subunits: NR1A/B andNR1A/2B. Subunit 2B (NR2B)
is particularly important, because of its role in the orga-
nization of sensory pathways and in the development of
neuropathic pain [18, 19].
A previous study has shown that propofol acts as aNMDA
receptor antagonist on the NR1 subunit. This phenomenon
was mediated by a signaling mechanism involving the activa-
tion of protein phosphatase 2A and thusmay have some effect
on reducing opioid-induced hyperalgesia [20].
Tyrosine phosphorylation in the NR2B subunit has an
important role in the induction of long-term potentiation,
a phenomenon associated with central sensitization [21] and
with the onset and development of inflammatory hyperalge-
sia [11]. Remifentanil-induced hyperalgesia has been shown
to lead to a considerable increase in tyrosine phosphorylation
in the NR2B subunit, and this increase may be prevented
by ketamine [5]. Yuan et al. suggest that glycogen synthase
kinase- (GSK-) 3 beta contributes to the development of
remifentanil-induced hyperalgesia through the regulation of
NMDA receptor subunits (NR1 and NR2B) in the spinal cord
and that inhibition of GSK-3 beta may be effective in the
treatment of hyperalgesia [22].
Kingston et al. [20] showed the antagonist effect of
propofol on NMDA receptors. Cerebral mechanisms may
be important for the results obtained by the interaction
between remifentanil and S-ketamine, because several pain
pathways are influenced differently by one of the two
drugs. Remifentanil directly inhibits nociceptive information
through opioid receptors located in the nervous system,
whereas S(+)-ketamine acts on brain structures such as insula
and anterior cortex, thus modulating the emotional aspect
of pain [23]. Gupta et al. suggest an important synergism
between ketamine and opioids [24]. In the S(+)-ketamine
group, there was a decrease in propofol and remifentanil
consumption, but future studies are needed to establish
more accurate correlations and conclusions on the specific
interactions between these drugs.
The blockade of NMDA receptor with the administration
of ketamine suppressed the development of opioid-induced
hyperalgesia and injury-induced central sensitization even
whenketaminewas given at subanesthetic doses [25]. Clinical
studies have demonstrated the efficacy of ketamine in the
control of acute postoperative pain in several surgical proce-
dures. Results have shown reduced pain scores and analgesic
consumption even after the end of the duration of action of
ketamine.
A systematic review concluded that intravenous ketamine
is an effective adjunct for postoperative analgesia, being par-
ticularly beneficial in abdominal, thoracic, and orthopedic
surgeries [6]. However, an opposite result was found by a
meta-analysis on the use of NMDA receptor antagonists to
control pain and remifentanil-induced hyperalgesia [2].
The reduced remifentanil consumption in the S(+)-
ketamine group may have contributed to reduction of post-
operative hyperalgesia. Guignard et al. concluded that higher
doses of remifentanil in the intraoperative period lead to an
increase in pain and in the postoperative consumption of
morphine [9].
Hang et al. concluded that the effective dose of ketamine
in 50% and 95% of patients (ED
50
and ED
95
) for preven-
tion of postoperative hyperalgesia after remifentanil-based
anesthesia was 0.24mg/kg and 0.33mg/kg, respectively [15].
In another study, Untergehrer et al. used S(+)-ketamine
at continuous infusion rates from 0.25 to 0.50mg⋅kg⋅h as
subanesthetic doses [1].
The rate of continuous S(+)-ketamine infusion used
in this study (0.3mg⋅kg−1⋅h−1) is associated with effective
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analgesia [1, 15], whereas higher doses of S(+)-ketamine are
associated with side effects leading to cognitive changes, such
as hallucinations and unpleasant dreams, and with mood,
perception, and consciousness changes. According to the
pharmacokinetic model proposed by White et al. [26], a
0.3mg/kg/h infusion for 16 minutes would lead to a concen-
tration effect of 70 ng/mL. Since our surgical team started
to perform surgery 11 minutes after anesthetic induction, on
average, we decided to start the infusion 5 minutes before
anesthetic induction. Koppert et al. used a similar dose of
S ketamine in another study, also without an initial bolus
[27].
The current study evaluated the effect of S(+)-ketamine
using pain scores and overall consumption of morphine
recorded over a 12-hour period after the end of surgery.
The presence of any postoperative side effects was also
noted. Despite the lower morphine requirement in the S(+)-
ketamine group, the incidence of postoperative side effects
did not differ significantly between groups.
The main limitation of this study is the lack of a longer
follow-up throughout the postoperative period, which pre-
vented us from drawing a more comprehensive conclusion
on postoperative pain control. The decision to evaluate
patients throughout a 12-hour period is based on the mean
postoperative length of stay of patients undergoing laparo-
scopic cholecystectomy in our service. In addition, we believe
that studying pain control in this surgery is of paramount
importance, because this procedure is capable of releasing
nociceptive mediators and requires a short hospital stay [28].
5. Conclusions
The present study tested the hypothesis that continuous
infusion of low-dose S(+)-ketamine is more effective than
placebo in the control of postoperative pain. Despite the
lack of statistical difference in morphine consumption dur-
ing PACU stay, this hypothesis is supported by our find-
ings that continuous S(+)-ketamine infusion at a rate of
0.3mg⋅kg−1⋅h−1 during laparoscopic cholecystectomy under
target-controlled intravenous anesthesia reduced the overall
need for postoperative morphine and VNS pain scores at
all time points assessed. However, we recognize that further
studies with longer postoperative follow-up are required to
better understand the correlations found in this study.
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